Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 59.92% is in line with its 5-year average of 63.00%, around the middle of its 5-year range (54.46%–69.43%).
As of the fiscal period ended Tuesday, June 30, 2026. 2.31% below its 12-month average of 61.33%.
Reported quarterly debt to assets ratio; no daily interpolation.
DEBT TO ASSETS RATIO
59.92%
DEBT TO ASSETS RATIO AVG TTM
61.33%
DEBT TO ASSETS RATIO AVG 3Y
64.77%
DEBT TO ASSETS RATIO AVG 5Y
63.00%
DEBT TO ASSETS RATIO AVG 10Y
56.14%
DEBT TO ASSETS RATIO AVG 15Y
52.31%
DEBT TO ASSETS RATIO AVG 20Y
46.62%
CURRENT VS TTM AVG
-2.31%
CURRENT VS 3Y AVG
-7.49%
CURRENT VS 5Y AVG
-4.89%
CURRENT VS 10Y AVG
+6.73%
CURRENT VS 15Y AVG
+14.55%
CURRENT VS 20Y AVG
+28.53%
SECTOR MEDIAN · HEALTHCARE
0.28%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+21298.92%
vs the sector median at left
Amgen Inc.
Market Cap
$214.33B
Debt to Assets Ratio
59.92%
TTM Avg
61.33%
3Y Avg
64.77%
5Y Avg
63.00%
Market Cap
$224.47B
Debt to Assets Ratio
0.38%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$183.26B
Debt to Assets Ratio
0.30%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$181.80B
Debt to Assets Ratio
0.53%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$145.27B
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$134.68B
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amgen Inc. (AMGN) | $214.33B | 59.92% | 61.33% | 64.77% | 63.00% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.47B | 0.38% | N/A | N/A | N/A |
| Novo Nordisk A/S (NVO)vs › | $201.85B | 0.24% | N/A | N/A | N/A |
| Abbott Laboratories (ABT)vs › | $183.26B | 0.30% | N/A | N/A | N/A |
| Gilead Sciences, Inc. (GILD)vs › | $181.80B | 0.53% | N/A | N/A | N/A |
| AstraZeneca PLC (AZN)vs › | $250.54B | 0.28% | N/A | N/A | N/A |
| Pfizer Inc. (PFE)vs › | $159.04B | 0.31% | N/A | N/A | N/A |
| Danaher Corporation (DHR)vs › | $145.27B | 0.29% | N/A | N/A | N/A |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $134.68B | 0.07% | N/A | N/A | N/A |
| Bristol-Myers Squibb Company (BMY)vs › | $133.05B | 0.49% | N/A | N/A | N/A |
Debt/Assets
59.9%
Debt/Equity
4.90
Current Ratio
1.37
Interest Coverage
3.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 59.92% |
| 2026-03-31 | 61.97% |
| 2025-12-31 | 60.28% |
| 2025-09-30 | 60.56% |
| 2025-06-30 | 63.94% |
| 2025-03-31 | 64.21% |
| 2024-12-31 | 65.44% |
| 2024-09-30 | 66.46% |
| 2024-06-30 | 68.91% |
| 2024-03-31 | 68.85% |
| 2023-12-31 | 66.51% |
| 2023-09-30 | 66.79% |
| 2023-06-30 | 68.18% |
| 2023-03-31 | 69.43% |
| 2022-12-31 | 59.80% |
| 2022-09-30 | 60.76% |
| 2022-06-30 | 61.59% |
| 2022-03-31 | 62.26% |
| 2021-12-31 | 54.46% |
| 2021-09-30 | 57.82% |
| 2021-06-30 | 54.84% |
| 2021-03-31 | 52.26% |
| 2020-12-31 | 52.40% |
| 2020-09-30 | 53.05% |
| 2020-06-30 | 52.64% |
| 2020-03-31 | 51.64% |
| 2019-12-31 | 50.08% |
| 2019-09-30 | 50.04% |
| 2019-06-30 | 51.56% |
| 2019-03-31 | 51.60% |
| 2018-12-31 | 51.09% |
| 2018-09-30 | 51.13% |
| 2018-06-30 | 50.97% |
| 2018-03-31 | 49.94% |
| 2017-12-31 | 44.20% |
| 2017-09-30 | 44.54% |
| 2017-06-30 | 44.05% |
| 2017-03-31 | 43.79% |
| 2016-12-31 | 44.57% |
| 2016-09-30 | 45.20% |
| 2016-06-30 | 44.02% |
| 2016-03-31 | 45.67% |
| 2015-12-31 | 43.91% |
| 2015-09-30 | 44.19% |
| 2015-06-30 | 44.87% |
| 2015-03-31 | 44.00% |
| 2014-12-31 | 44.51% |
| 2014-09-30 | 46.60% |
| 2014-06-30 | 47.93% |
| 2014-03-31 | 47.79% |
| 2013-12-31 | 48.59% |
| 2013-09-30 | 47.64% |
| 2013-06-30 | 45.46% |
| 2013-03-31 | 46.27% |
| 2012-12-31 | 48.86% |
| 2012-09-30 | 47.75% |
| 2012-06-30 | 46.68% |
| 2012-03-31 | 43.47% |
| 2011-12-31 | 43.85% |
| 2011-09-30 | 31.17% |
| 2011-06-30 | 29.68% |
| 2011-03-31 | 25.53% |
| 2010-12-31 | 30.73% |
| 2010-09-30 | 30.53% |
| 2010-06-30 | 28.75% |
| 2010-03-31 | 28.90% |
| 2009-12-31 | 26.75% |
| 2009-09-30 | 28.18% |
| 2009-06-30 | 29.53% |
| 2009-03-31 | 30.52% |
| 2008-12-31 | 27.92% |
| 2008-09-30 | 30.21% |
| 2008-06-30 | 30.99% |
| 2008-03-31 | 30.94% |
| 2007-12-31 | 32.27% |
| 2007-09-30 | 33.82% |
| 2007-06-30 | 34.31% |
| 2007-03-31 | 22.46% |
| 2006-12-31 | 26.67% |
| 2006-09-30 | 27.64% |
| 2006-06-30 | 28.77% |
| 2006-03-31 | 28.62% |
| 2005-12-31 | 13.51% |
| 2005-09-30 | 13.57% |
| 2005-06-30 | 14.08% |
| 2005-03-31 | 14.38% |
| 2004-12-31 | 17.49% |
| 2004-09-30 | 11.58% |
| 2004-06-30 | 11.88% |
| 2004-03-31 | 11.88% |
| 2003-12-31 | 11.77% |
| 2003-09-30 | 11.87% |
| 2003-06-30 | 12.16% |
| 2003-03-31 | 12.45% |
| 2002-12-31 | 12.97% |
| 2002-09-30 | 13.32% |
